Abstract
Purpose: To present the state-of-the-art of subthreshold diode laser micropulse photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema (DME).
Method: To review the role and evolution of retinal laser treatment for DME.
Results: Thermal laser retinal photocoagulation has been the cornerstone of treatment for diabetic macular edema for over four decades. Throughout, laser induced retinal damage produced by conventional photocoagulation has been universally accepted as necessary to produce a therapeutic benefit, despite the inherent risks, adverse effects and limitations of thermally destructive treatment. Recently, SDM, performed as invisible retinal phototherapy for DME, has been found to be effective in the absence of any retinal damage or adverse effect, fundamentally altering our understanding of laser treatment for retinal disease.
Summary: The discovery of clinically effective and harmless SDM treatment for DME offers exciting new information that will improve our understanding of laser treatment for retinal disease, expand treatment indications, and improve patient outcomes.
Keywords: Subthreshold, invisible, diode laser, micropulse, photocoagulation, phototherapy, photostimulation, diabetes, diabetic retinopathy, diabetic macular edema, diabetic retinopathy
Current Diabetes Reviews
Title:Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
Volume: 8 Issue: 4
Author(s): Jeffrey K. Luttrull and Giorgio Dorin
Affiliation:
Keywords: Subthreshold, invisible, diode laser, micropulse, photocoagulation, phototherapy, photostimulation, diabetes, diabetic retinopathy, diabetic macular edema, diabetic retinopathy
Abstract: Purpose: To present the state-of-the-art of subthreshold diode laser micropulse photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema (DME).
Method: To review the role and evolution of retinal laser treatment for DME.
Results: Thermal laser retinal photocoagulation has been the cornerstone of treatment for diabetic macular edema for over four decades. Throughout, laser induced retinal damage produced by conventional photocoagulation has been universally accepted as necessary to produce a therapeutic benefit, despite the inherent risks, adverse effects and limitations of thermally destructive treatment. Recently, SDM, performed as invisible retinal phototherapy for DME, has been found to be effective in the absence of any retinal damage or adverse effect, fundamentally altering our understanding of laser treatment for retinal disease.
Summary: The discovery of clinically effective and harmless SDM treatment for DME offers exciting new information that will improve our understanding of laser treatment for retinal disease, expand treatment indications, and improve patient outcomes.
Export Options
About this article
Cite this article as:
K. Luttrull Jeffrey and Dorin Giorgio, Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review, Current Diabetes Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339912800840523
DOI https://dx.doi.org/10.2174/157339912800840523 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Role of Non-Coding RNA of Human Platelet in Cardiovascular Disease
Current Medicinal Chemistry Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Insights into the Platelet Releasate
Current Pharmaceutical Design Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Current Molecular Understanding and Future Treatment Strategies for Pathologic Ocular Neovascularization
Current Molecular Medicine Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology